Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Context Therapeutics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Pharmaceutical Preparations
No intraday reading yet this session.
Context Therapeutics Inc. has 7 disclosed suppliers and 0 disclosed customers. Each one is named in an SEC filing, either Context Therapeutics Inc.’s own annual report or the counterparty’s, and carries the sentence that discloses it.
No filing we have read names a customer of Context Therapeutics Inc.. Customers appear here when Context Therapeutics Inc. names them, or when a company names Context Therapeutics Inc. as a supplier in its own annual report.
Sources
sec edgar · verbatim disclosureEach tie, with the sentence that disclosed it. Open a row for the wording and the filing it came from.
“On September 23, 2024, we entered into a license agreement (the "BioAtla License Agreement") with BioAtla, Inc. ("BioAtla"), pursuant to which we obtained an exclusive, worldwide license to develop, manufacture and commercialize two licensed antibodies (the "BioAtla Assets"), including BA3362 (renamed by the Company as CT-202), BioAtla's Nectin-4 x CD3 TCE.”
FILING10-K0001628280-26-020498cik 0001842952
“In April 2021, we entered into a collaboration and licensing agreement with Integral Molecular, Inc. ("Integral") (the "Integral License Agreement") for the development of a CLDN6 bsAb for cancer therapy.”
FILING10-K0001628280-26-020498cik 0001842952
“To date, we have obtained active pharmaceutical ingredients ("API") and drug product for our product candidates from several third-party contract manufacturers, including Lonza Sales AG ("Lonza Sales") and Lonza AG ("Lonza AG", and collectively with Lonza Sales, "Lonza") and Just-Evotec Biologics, Inc.”
FILING10-K0001628280-26-020498cik 0001842952
“In consideration of the Transferred Assets, we made a one-time payment to Link of $3.75 million.”
FILING10-K0001628280-26-020498cik 0001842952
“To date, we have obtained active pharmaceutical ingredients ("API") and drug product for our product candidates from several third-party contract manufacturers, including Lonza Sales AG ("Lonza Sales") and Lonza AG ("Lonza AG", and collectively with Lonza Sales, "Lonza") and Just-Evotec Biologics, Inc.”
FILING10-K0001628280-26-020498cik 0001842952
“To date, we have obtained active pharmaceutical ingredients ("API") and drug product for our product candidates from several third-party contract manufacturers, including Lonza Sales AG ("Lonza Sales") and Lonza AG ("Lonza AG", and collectively with Lonza Sales, "Lonza") and Just-Evotec Biologics, Inc.”
FILING10-K0001628280-26-020498cik 0001842952
“On December 2, 2024, we entered into a Sales Agreement (the "ATM Sales Agreement") with Leerink Partners LLC (the "Agent").”
FILING10-K0001628280-26-020498cik 0001842952
Watchlist prices, news filtered to it, and its next report on your desk.
CNTX (Context Therapeutics Inc.) has 7 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for the filing sentence that discloses it; select again to open the company. Lines are disclosed suppliers and customers, coloured by industry; the closer to the centre, the more the filings disclose. A dot is green or red by today’s move. Extended: satellites hang off single companies, not bundled sectors.